A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Binimetinib (Primary) ; Ribociclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma; Novartis Pharmaceuticals
- 22 Feb 2018 Status changed from active, no longer recruiting to completed.
- 06 Jan 2018 This trial has been completed in Italy.
- 29 Sep 2017 Planned End Date changed from 30 Nov 2017 to 30 Nov 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History